Ignacio Blanco, Isidro Diego, Patricia Bueno, Francisco Casas-Maldonado, Marc Miravitlles
European Respiratory Journal 2019 54: 1900610; DOI: 10.1183/13993003.00610-2019
Existing data on chronic obstructive pulmonary disease (COPD) prevalence are irregularly distributed around the world, and in many geographic regions data are scarce or even nonexistent. This fact hinders the implementation of adequate preventive and therapeutic interventions to reduce the high burden and costs of COPD . In the current study, we have used the Geographic Information System (GIS) inverse distance weighted (IDW) interpolation technique with the objective of visualising spatial data of COPD prevalence in the world and obtaining a visual impression of the magnitude of this global health problem. GIS has been recognised as an effective tool to display the geographical distribution of data, even when they are few and widely separated, as is the case with the prevalence of COPD [2–4].
Author contributions: All the authors have contributed to the elaboration of the manuscript and have approved its final version. I. Blanco, I. Diego and M. Miravitlles are the guarantors of the paper.
Conflict of interest: I. Blanco has nothing to disclose.
Conflict of interest: I. Diego has nothing to disclose.
Conflict of interest: P. Bueno has nothing to disclose.
Conflict of interest: F. Casas-Maldonado has nothing to disclose.
Conflict of interest: M. Miravitlles reports speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols, and research grants from GlaxoSmithKline and Grifols, outside the submitted work.